Charles Haworth is a Respiratory Consultant working within the Cambridge Centre for Lung Infection at Royal Papworth Hospital where he specialises in treating adults with cystic fibrosis, bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He was senior author of the International NTM guidelines published in Thorax in 2015 and first author of the British Thoracic Society NTM guidelines published in 2017. He also co-authored the BTS bronchiectasis and European Respiratory Society Bronchiectasis guidelines published in 2017 and 2019, respectively. He collaborates with Professor Andres Floto at the University of Cambridge on a variety of experimental medicine studies and is a member of the European Commission funded “Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)” and “CFMATTERS” consortia. He is co-chief investigator of two international novel therapy clinical trials in people with bronchiectasis and a member of the European Bronchiectasis Registry (EMBARC) Steering Committee and Scientific Committee. He is a site Principal Investigator for the European Cystic Fibrosis Society Clinical Trials network, a member of the CF Trust Strategic Research Centre grant committee, a member of the CHEST editorial board and a member of the CF Foundation Data Safety Monitoring Board. He is also a founding member and executive committee of the UK Cystic Fibrosis Medical Association, which represents the UK CF medical community.